REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pulmonx Corporation, a leader in interventional pulmonology, today announced that Glen French has joined the company as President, Chief Executive Officer and member of the Board of Directors. Mr. French possesses deep experience leading and transforming pulmonology, respiratory and endoscopic businesses. Most recently, he was CEO of ApniCure, a developer of proprietary devices for the treatment of obstructive sleep apnea (OSA) and other sleep disorders.
Prior to ApniCure, Mr. French was Co-Founder, President and CEO of Asthmatx, a developer of a catheter-based device for the treatment of asthma. At Asthmatx, he was responsible for guiding the company through clinical testing, FDA PMA approval, manufacturing expansion, initial product launch and acquisition by Boston Scientific Corporation. Following the acquisition, Mr. French served as President, Pulmonary Endoscopy for Boston Scientific's Endoscopy Division. Earlier, Mr. French co-founded and led Broncus Technologies, developer of minimally-invasive devices for the diagnosis and treatment of lung disease, as well as NDO Surgical, provider of natural orifice surgical devices.
“Glen has spent more than 15 years leading companies focused on the development of interventional pulmonology products. Glen’s deep market knowledge and experience will be invaluable as we continue to build momentum for Pulmonx’s products in the market,” said Dr. Rodney Perkins, Pulmonx Founder and Chairman of the Board.
“There is a large need for effective, less invasive treatments for severe emphysema, and Pulmonx offers compelling technologies that fill this gap,” said Mr. French. “Through our good work we will help reduce the suffering and restore the quality of life of emphysema patients worldwide with both existing and new therapies.”
The Zephyr® EBV is a minimally invasive treatment for severe emphysema that has been proven over a decade of clinical experience to significantly improve lung function, exercise tolerance and quality of life for patients receiving treatment. A proprietary diagnostic is run prior to the procedure to identify likely responders with a high degree of certainty. In the procedure, tiny, one-way valves are placed in the lungs to block airflow to hyperinflated regions to achieve lung volume reduction. As a result, the remaining healthy regions may function more efficiently, enabling better breathing and improving quality of life. More than 25,000 Zephyr EBVs have been implanted globally.
Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is an interventional pulmonology company focused on developing life-changing, cost-effective technologies that improve the lives of patients suffering from lung disease worldwide. For more information, visit www.pulmonx.com.
The Zephyr® EBV is an investigational device in the United States. Limited by U.S. law to investigational use.